UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee disagree

Health economics review, 2019-12, Vol.9 (35), p.1-15, Article 35

2019

Volltextzugriff (PDF)

Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?

Health policy (Amsterdam), 2020-09, Vol.124 (9), p.943-951

2020

Volltextzugriff (PDF)

The Risky Business of Drug Development: The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey – As Illustrated By The Decisions Of Germany's Gemeinsamer Bundesausschuss (G-Ba)

Value in health, 2014-11, Vol.17 (7), p.A439-A439

2014

Volltextzugriff (PDF)

Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology

Value in health, 2014-11, Vol.17 (7), p.A658-A658

2014

Volltextzugriff (PDF)

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources

Annals of the rheumatic diseases, 2003-06, Vol.62 (6), p.544-550

2003

Volltextzugriff (PDF)

Arzneimittel – Sicherheit, Nutzen und Zusatznutzen

Der Merkurstab, 2024, Vol.77 (4), p.244-249

Ruof, J.

2024

Volltextzugriff (PDF)

PRM162 Appropriate Comparative Treatments for Early Benefit Assessment (EBA) in Germany. Comparing the Suggestions by the Joint Federal Committee (GBA) and the Pharmaceutical Companies

Value in health, 2012-11, Vol.15 (7), p.A490-A490

2012

Volltextzugriff (PDF)

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

Value in health, 2014-11, Vol.17 (7), p.A427-A427

2014

Volltextzugriff (PDF)

Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

Value in health, 2013-11, Vol.16 (7), p.A575-A575

2013

Volltextzugriff (PDF)

PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments

Value in health, 2012-11, Vol.15 (7), p.A315-A315

2012

Volltextzugriff (PDF)

PRM5 Attribution of Benefit to the Three Disease Dimensions Mortality, Morbidity, Quality of Life Within Early Benefit Assessment (EBA) in Germany

Value in health, 2012-11, Vol.15 (7), p.A460-A460

2012

Volltextzugriff (PDF)

Content comparison of health status measures for obesity based on the international classification of functioning, disability and health

International Journal of Obesity, 2006-12, Vol.30 (12), p.1791-1799

2006

Volltextzugriff (PDF)

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

International Journal of Obesity, 2005-05, Vol.29 (5), p.517-523

2005

Volltextzugriff (PDF)

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)

Rheumatology (Oxford, England), 1999-06, Vol.38 (6), p.535-542

1999

Volltextzugriff (PDF)

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

International Journal of Obesity, 2005-08, Vol.29 (8), p.975-982

2005

Volltextzugriff (PDF)

Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns

Preventive medicine, 2002-07, Vol.35 (1), p.48-53

2002

Volltextzugriff (PDF)

PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective

Value in health, 2012-11, Vol.15 (7), p.A437-A437

2012

Volltextzugriff (PDF)

Produktivitätskosten der rheumatoiden Arthritis in Deutschland : Kostenzusammensetzung und Prädiktion der Hauptkostenkomponenten

Zeitschrift für Rheumatologie, 2006-10, Vol.65 (6), p.527-534

2006

Volltextzugriff (PDF)

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis

Journal of rheumatology, 2001-03, Vol.28 (3), p.657

2001

Volltextzugriff (PDF)

PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

Value in health, 2019-11, Vol.22, p.S611-S611

2019

Volltextzugriff (PDF)

PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

Value in health, 2019-11, Vol.22, p.S807-S807

2019

Volltextzugriff (PDF)

Costs in rheumatology : results and lessons learned from the 'Hannover Costing Study'

Rheumatology international, 2006-06, Vol.26 (8), p.704-711

2006

Volltextzugriff (PDF)

Direct costs related to rheumatoid arthritis: the patient perspective

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1456-1461

2005

Volltextzugriff (PDF)

Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis

Zeitschrift für Rheumatologie, 2002-02, Vol.61 (1), p.21-29

2002

Volltextzugriff (PDF)

Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Value in health, 2016-11, Vol.19 (7), p.A466-A467

2016

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(147)

Publikationsform

Sprache

Englisch
(141)
Deutsch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Humans
(41)
Life Sciences & Biomedicine
(35)
Physical Sciences
(26)
Physics
(23)
Biological And Medical Sciences
(19)
Rheumatology
(19)
Arthritis, Rheumatoid - Economics
(18)
Female
(18)
Male
(18)
Medical Sciences
(18)
Middle Aged
(16)
Nuclear Physics And Radiation Physics
(16)
Physics Of Elementary Particles And Fields
(16)
Adult
(15)
Beta Decay
(14)
Germany
(14)
Rheumatoid Arthritis
(13)
Aged
(12)
Germanium
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee disagree

Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?

The Risky Business of Drug Development: The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey – As Illustrated By The Decisions Of Germany's Gemeinsamer Bundesausschuss (G-Ba)

Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources

Arzneimittel – Sicherheit, Nutzen und Zusatznutzen

PRM162 Appropriate Comparative Treatments for Early Benefit Assessment (EBA) in Germany. Comparing the Suggestions by the Joint Federal Committee (GBA) and the Pharmaceutical Companies

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments

PRM5 Attribution of Benefit to the Three Disease Dimensions Mortality, Morbidity, Quality of Life Within Early Benefit Assessment (EBA) in Germany

Content comparison of health status measures for obesity based on the international classification of functioning, disability and health

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns

PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective

Produktivitätskosten der rheumatoiden Arthritis in Deutschland : Kostenzusammensetzung und Prädiktion der Hauptkostenkomponenten

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis

PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

Costs in rheumatology : results and lessons learned from the 'Hannover Costing Study'

Direct costs related to rheumatoid arthritis: the patient perspective

Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis

Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Suchergebnisse filtern